Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
Abnormal Uterine Bleeding Associated With Hormonal Contraception
This article includes algorithms to help clinicians treat abnormal uterine bleeding in people using levonorgestrel intrauterine devices, depo-medroxyprogesterone acetate, progestin implant, progestin-only pills, and combined hormonal contraception. For patients with levonorgestrel intrauterine devices, physicians should first ensure that the device is correctly placed within the uterus, then consider nonsteroidal anti-inflammatory drugs as a first-line treatment for abnormal uterine bleeding; estradiol can be used if nonsteroidal anti-inflammatory drugs are ineffective. For depo-medroxyprogesterone acetate or progestin imp...
Source: American Family Physician - February 23, 2024 Category: Primary Care Authors: Sarina Schrager Kelita Fox Rachel Lee Source Type: research
A mouse model of oral contraceptive exposure: Depression, motivation, and the stress response
In this study, we developed and characterized a tractable mouse model of OC exposure with which to identify the mechanisms underlying OC modulation of brain, behavior, and mood. Specifically, we aimed to determine whether translationally relevant doses of OC-hormones in mice mimic changes in stress responsivity observed in humans taking OCs and describe behavioral changes during OC exposure. Young adult female C57Bl/6 N mice received daily ethinyl estradiol (EE) and levonorgestrel (LVNG) in 10 % sucrose, EE and drospirenone (DRSP) in 10 % sucrose, or 10 % sucrose alone. Translationally relevant doses of EE + LVNG-exposure,...
Source: Hormones and Behavior - December 7, 2023 Category: Endocrinology Authors: Kristen M Schuh Jabir Ahmed Esther Kwak Cecilia X Xu Tronjay T Davis Chloe B Aronoff Natalie C Tronson Source Type: research
A mouse model of oral contraceptive exposure: Depression, motivation, and the stress response
In this study, we developed and characterized a tractable mouse model of OC exposure with which to identify the mechanisms underlying OC modulation of brain, behavior, and mood. Specifically, we aimed to determine whether translationally relevant doses of OC-hormones in mice mimic changes in stress responsivity observed in humans taking OCs and describe behavioral changes during OC exposure. Young adult female C57Bl/6 N mice received daily ethinyl estradiol (EE) and levonorgestrel (LVNG) in 10 % sucrose, EE and drospirenone (DRSP) in 10 % sucrose, or 10 % sucrose alone. Translationally relevant doses of EE + LVNG-exposure,...
Source: Hormones and Behavior - December 7, 2023 Category: Endocrinology Authors: Kristen M Schuh Jabir Ahmed Esther Kwak Cecilia X Xu Tronjay T Davis Chloe B Aronoff Natalie C Tronson Source Type: research
Comparison of Estrogenic Components Used for Hormonal Contraception
Attempts have been made over the years to replace ethinyl estradiol (EE) in combined oral contraceptives (COCs) with the less potent natural estrogen estradiol (E2), or its prodrug, E2 valerate (E2V), to improve the safety and tolerability of COCs. Recently, a COC formulation incorporating a novel weak natural estrogen, estetrol (E4), combined with drospirenone, has become available. Here we present a comparative analysis of the three prevailing estrogens used in COCs, focusing on their structure-function relationships, receptor-binding affinity, potency, metabolism, pharmacokinetic parameters, and pharmacodynamics. (Source: Contraception)
Source: Contraception - October 18, 2023 Category: OBGYN Authors: Frank Z. Stanczyk, Sharon A. Winer, Jean-Michel Foidart, David F. Archer Source Type: research
Drospirenone and estetrol - evaluation of a newly approved novel oral contraceptive
Expert Opin Pharmacother. 2023 Sep 11. doi: 10.1080/14656566.2023.2247979. Online ahead of print.ABSTRACTINTRODUCTION: Estetrol (E4) is a native estrogen produced only by the fetal liver during pregnancy. E4 is the first new estrogen to be used in hormonal contraception since the introduction of oral contraceptives in 1960. Ethinyl estradiol, the most commonly used estrogen in oral contraceptives today, increases risks of thromboembolism and has other significant hepatic impacts, which induce important drug-drug interactions.On the other hand, Phase 2 E4 characterization studies demonstrated that E4 has negligible impacts ...
Source: Expert Opinion on Pharmacotherapy - September 11, 2023 Category: Drugs & Pharmacology Authors: Anita L Nelson Source Type: research
A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy
CONCLUSIONS: Research in PMD, MM, and CE commonly have overlapping study design and research methods, and similar effects of some interventions suggest the possibility of overlapping mechanisms contributing to their cyclical symptom presentation. Our scoping review is the first to summarize existing clinical trials in these three brain disorders, specifically focusing on hormonal treatment trials. We find that PMD has a stronger body of literature for ovulation-suppressing COC and GnRHa trials; the field of MM consists of extensive estrogen-based studies; and current consensus in CE focuses on progesterone supplementation ...
Source: Frontiers in Neuroendocrinology - August 24, 2023 Category: Endocrinology Authors: Jordan C Barone Mitchell P Butler Ashley Ross Anna Patterson Melissa Wagner-Schuman Tory A Eisenlohr-Moul Source Type: research
A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy
CONCLUSIONS: Research in PMD, MM, and CE commonly have overlapping study design and research methods, and similar effects of some interventions suggest the possibility of overlapping mechanisms contributing to their cyclical symptom presentation. Our scoping review is the first to summarize existing clinical trials in these three brain disorders, specifically focusing on hormonal treatment trials. We find that PMD has a stronger body of literature for ovulation-suppressing COC and GnRHa trials; the field of MM consists of extensive estrogen-based studies; and current consensus in CE focuses on progesterone supplementation ...
Source: Frontiers in Neuroendocrinology - August 24, 2023 Category: Endocrinology Authors: Jordan C Barone Mitchell P Butler Ashley Ross Anna Patterson Melissa Wagner-Schuman Tory A Eisenlohr-Moul Source Type: research
A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy
CONCLUSIONS: Research in PMD, MM, and CE commonly have overlapping study design and research methods, and similar effects of some interventions suggest the possibility of overlapping mechanisms contributing to their cyclical symptom presentation. Our scoping review is the first to summarize existing clinical trials in these three brain disorders, specifically focusing on hormonal treatment trials. We find that PMD has a stronger body of literature for ovulation-suppressing COC and GnRHa trials; the field of MM consists of extensive estrogen-based studies; and current consensus in CE focuses on progesterone supplementation ...
Source: Frontiers in Neuroendocrinology - August 24, 2023 Category: Endocrinology Authors: Jordan C Barone Mitchell P Butler Ashley Ross Anna Patterson Melissa Wagner-Schuman Tory A Eisenlohr-Moul Source Type: research
A scoping review of hormonal clinical trials in menstrual cycle-related brain disorders: Studies in premenstrual mood disorder, menstrual migraine, and catamenial epilepsy
CONCLUSIONS: Research in PMD, MM, and CE commonly have overlapping study design and research methods, and similar effects of some interventions suggest the possibility of overlapping mechanisms contributing to their cyclical symptom presentation. Our scoping review is the first to summarize existing clinical trials in these three brain disorders, specifically focusing on hormonal treatment trials. We find that PMD has a stronger body of literature for ovulation-suppressing COC and GnRHa trials; the field of MM consists of extensive estrogen-based studies; and current consensus in CE focuses on progesterone supplementation ...
Source: Frontiers in Neuroendocrinology - August 24, 2023 Category: Endocrinology Authors: Jordan C Barone Mitchell P Butler Ashley Ross Anna Patterson Melissa Wagner-Schuman Tory A Eisenlohr-Moul Source Type: research
